← 產業報告目錄

Gene Therapy for Blood Disorders Market Size, Share & Trends Analysis Report By Indication (Sickle Cell Anemia, β-thalassemia, Hemophilia B, Hemophilia A), By Mechanism of Action (Gene Therapy, Gene Editing), By Region, And Segment Forecasts, 2025-2034

出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-23頁數 185報告編號 INSIGHTACE-e479c90b38

授權報價

Single User PDF$4,500 USD
Global Site License PDF$9,500 USD
洽詢購買 申請 Sample

報告摘要

A CAGR of 15.3% is forecasted for the global Gene Therapy for Blood Disorders Market over the assessment period of 2025 through 2034. At its core, Gene Therapy for Blood Disorders pertains to The Arena of Gene Therapy is determined to outline a path to the clinic and the market. Stakeholders across the healthcare landscape are surgingly turning to these solutions to meet contemporary demands. Several factors contribute to this trajectory, including heightened appetite for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives. From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities. From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and surging investment in the sector. The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion. The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Gene Therapy for Blood Disorders Market Snapshot Chapter 4. Global Gene Therapy for Blood Disorders Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Penetration & Growth Prospect Mapping 4.6. Clinical Trial/Pipeline Analysis 4.7. Industry Analysis – Porter's Five Forces Analysis 4.8. Competitive Landscape & Market Share Analysis 4.9. Technology Advancement in Gene Therapy for Blood Disorders Market 4.10. Key Trends in the Market Chapter 5. Market Segmentation 1: Indication Estimates & Trend Analysis 5.1. Indication Type & Market Share, 2024 & 2034 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication: 5.2.1. Sickle Cell Anemia 5.2.2. β-thalassemia 5.2.3. Hemophilia B 5.2.4. Hemophilia A Chapter 6. Market Segmentation 1: Mechanism of Action Estimates & Trend Analysis 6.1. Mechanism of Action Type & Market Share, 2024 & 2034 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Mechanism of Action: 6.2.1. Gene Therapy 6.2.2. Gene Editing Chapter 7. Gene Therapy for Blood Disorders Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. North America 7.1.1. North America Gene Therapy for Blood Disorders Market revenue (US$ Million) estimates and forecasts by Indication, 2021-2034 7.1.2. North America Gene Therapy for Blood Disorders Market revenue (US$ Million) estimates and forecasts by Mechanism of Action, 2021-2034 7.1.3. North America Gene Therapy for Blood Disorders Market revenue (US$ Million) estimates and forecasts by country, 2021-2034 7.1.3.1. U.S. 7.1.3.2. Canada 7.2. Europe 7.2.1. Europe Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034 7.2.2. Europe Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034 7.2.3. Europe Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034 7.2.3.1. Germany 7.2.3.2. Poland 7.2.3.3. France 7.2.3.4. Italy 7.2.3.5. Spain 7.2.3.6. UK 7.2.3.7. Rest of Europe 7.3. Asia Pacific 7.3.1. Asia Pacific Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034 7.3.2. Asia Pacific Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034 7.3.3. Asia Pacific Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034 7.3.3.1. China 7.3.3.2. India 7.3.3.3. Japan 7.3.3.4. Australia 7.3.3.5. Rest of Asia Pacific 7.4. Latin America 7.4.1. Latin America Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034 7.4.2. Latin America Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034 7.4.3. Latin America Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034 7.4.3.1. Brazil 7.4.3.2. Rest of Latin America 7.5. MEA 7.5.1. MEA revenue Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034 7.5.2. MEA Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034 7.5.3. MEA Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034 Chapter 8. Competitive Landscape 8.1. Major Mergers and Acquisitions/Strategic Alliances 8.2. Company Profiles 8.2.1. Biomarin Therapeutics 8.2.2. Spark Therapeutics 8.2.3. Shire 8.2.4. bluebird bio, Inc. 8.2.5. CRISPR Therapeutics 8.2.6. Expression Therapeutics LLC 8.2.7. Medgenics 8.2.8. OrphageniX 8.2.9. Freeline Therapeutics 8.2.10. Errant Gene Therapeutics 8.2.11. Sangamo Therapeutics 8.2.12. Sigilon Therapeutics, Inc. 8.2.13. uniQure 8.2.14. Angiocrine Bioscience 8.2.15. Sanofi Genzyme 8.2.16. Other Prominent Players

量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們